Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

The recent FDA approvals of two treatments for molluscum contagiosum may represent a shift in how clinicians view this disease, according to a speaker at Masters of Pediatric Dermatology.In an ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...